<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21445287</article-id><article-id pub-id-type="pmc">3061857</article-id><article-id pub-id-type="publisher-id">10-PONE-RA-19149R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0014771</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Nutrition</subject><subject>Genetics and Genomics/Gene Expression</subject><subject>Nutrition/Deficiencies</subject></subj-group></article-categories><title-group><article-title>Effects of Selenium Supplementation on Selenoprotein Gene Expression
and Response to Influenza Vaccine Challenge: A Randomised Controlled
Trial</article-title><alt-title alt-title-type="running-head">Se &#x00026; Selenoprotein Genes</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Goldson</surname><given-names>Andrew J.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fairweather-Tait</surname><given-names>Susan J.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Armah</surname><given-names>Charlotte N.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bao</surname><given-names>Yongping</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Broadley</surname><given-names>Martin R.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dainty</surname><given-names>Jack R.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Furniss</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hart</surname><given-names>David J.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Teucher</surname><given-names>Birgit</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hurst</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Institute of Food Research, Norwich Research Park, Norwich, United
Kingdom</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Norwich Medical School, University of East Anglia, Norwich, United
Kingdom</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>School of Biosciences, University of Nottingham, Sutton Bonington,
Loughborough, United Kingdom</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Gregson</surname><given-names>Aric</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of California Los Angeles, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>R.hurst1@uea.ac.uk</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: SJFT MRB BT RH. Performed the
experiments: AJG CNA MRB CF DJH RH. Analyzed the data: AJG SJFT CNA JRD CF
DJH RH. Contributed reagents/materials/analysis tools: YB MRB BT RH. Wrote
the paper: AJG SJFT RH. Contributed to the paper and approved the final
draft: CNA YB MRB JRD CF DJH BT.</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>21</day><month>3</month><year>2011</year></pub-date><volume>6</volume><issue>3</issue><elocation-id>e14771</elocation-id><history><date date-type="received"><day>21</day><month>5</month><year>2010</year></date><date date-type="accepted"><day>8</day><month>2</month><year>2011</year></date></history><permissions><copyright-statement>Goldson et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>The uncertainty surrounding dietary requirements for selenium (Se) is partly
due to limitations in biomarkers of Se status that are related to health
outcomes. In this study we determined the effect of different doses and
forms of Se on gene expression of selenoprotein S (SEPS1), selenoprotein W
(SEPW1) and selenoprotein R (SEPR), and responses to an immune function
challenge, influenza vaccine, were measured in order to identify functional
markers of Se status.</p></sec><sec><title>Methods and Findings</title><p>A 12 week human dietary intervention study was undertaken in 119 volunteers
who received placebo, 50, 100 or 200 &#x000b5;g/day Se-enriched yeast
(Se-yeast) or meals containing unenriched or Se-enriched onions (50
&#x000b5;g/day). Gene expression was quantified in RNA samples extracted from
human peripheral blood mononuclear cells (PBMC's) using quantitative
RT-PCR. There was a significant increase in SEPW1 mRNA in the Se-enriched
onion group (50 &#x000b5;g/day) compared with the unenriched onion group. SEPR
and SEPW1 did not change significantly over the duration of the
supplementation period in the control or Se-yeast groups, except at week 10
when SEPW1 mRNA levels were significantly lower in the 200 &#x000b5;g/day
Se-yeast group compared to the placebo group. Levels of SEPS1 mRNA increased
significantly 7 days after the influenza vaccine challenge, the magnitude of
the increase in SEPS1 gene expression was dose-dependent, with a
significantly greater response with higher Se supplementation.</p></sec><sec><title>Conclusions</title><p>This novel finding provides preliminary evidence for a role of SEPS1 in the
immune response, and further supports the relationship between Se status and
immune function.</p></sec><sec><title>Trial Registration</title><p>ClinicalTrials.gov [<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT00279812">NCT00279812</ext-link>]</p></sec></abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Selenium (Se) is involved in a wide variety of functions in the human body <xref rid="pone.0014771-Rayman1" ref-type="bibr">[1]</xref> and has been
reported to reduce the incidence and mortality risk of prostate, colon and lung
cancer <xref rid="pone.0014771-Bleys1" ref-type="bibr">[2]</xref>-<xref rid="pone.0014771-Ip1" ref-type="bibr">[6]</xref>. Se also has an
important role in the function of the immune system <xref rid="pone.0014771-Hoffmann1" ref-type="bibr">[7]</xref> as it has been demonstrated to
be improved in Se-deficient populations given Se supplements <xref rid="pone.0014771-Hoffmann1" ref-type="bibr">[7]</xref>, <xref rid="pone.0014771-Broome1" ref-type="bibr">[8]</xref>. In several European populations
Se intakes are below recommended intakes <xref rid="pone.0014771-Rayman2" ref-type="bibr">[9]</xref> and therefore there is a need to
evaluate the consequences of sub-optimal status to enable public health policies to
be developed <xref rid="pone.0014771-Thomson1" ref-type="bibr">[10]</xref>.</p><p>Long-term status may be assessed from erythrocyte, hair or toenail Se content.
However, such measures have no universally accepted reference ranges due to large
geographical variations in Se intake <xref rid="pone.0014771-Thomson1" ref-type="bibr">[10]</xref>. Plasma Se is commonly used as
a short-term measure of status but different forms of dietary Se result in different
responses in plasma Se concentration <xref rid="pone.0014771-Burk1" ref-type="bibr">[11]</xref> and the Se present in the circulation may not be
available for incorporation into functional proteins <xref rid="pone.0014771-Neve1" ref-type="bibr">[12]</xref>; organic forms such as
selenomethionine may be readily incorporated into plasma albumin or erythrocyte
haemoglobin whereas inorganic forms may not <xref rid="pone.0014771-Burk2" ref-type="bibr">[13]</xref>. Measurement of the expression of
individual selenoproteins may therefore provide a more appropriate measure of Se
status <xref rid="pone.0014771-Patching1" ref-type="bibr">[14]</xref>. The
human selenoproteome is comprised of 25 selenoproteins <xref rid="pone.0014771-Kryukov1" ref-type="bibr">[15]</xref> and it is therefore likely
that the combination of a number of key selenoproteins will determine Se status
<xref rid="pone.0014771-Thomson1" ref-type="bibr">[10]</xref>, <xref rid="pone.0014771-Elsom1" ref-type="bibr">[16]</xref>.</p><p>At present, recommendations for Se intake are based on maximising plasma glutathione
peroxidase (GPx3) levels <xref rid="pone.0014771-Institute1" ref-type="bibr">[17]</xref> but there is considerable debate as to the
appropriateness of this endpoint <xref rid="pone.0014771-Thomson1" ref-type="bibr">[10]</xref>. Red blood cell glutathione peroxidase (GPx1) has proved
useful for identifying individuals/populations with low Se status, but as with
plasma GPx3, the enzyme activity plateau is reached relatively quickly as Se intake
is increased <xref rid="pone.0014771-Neve1" ref-type="bibr">[12]</xref>.
Glutathione peroxidase 4 (GPx4) has also been proposed as a possible functional
marker of Se status <xref rid="pone.0014771-Brown1" ref-type="bibr">[18]</xref>, but there is significant heterogeneity in the data from
published studies to date <xref rid="pone.0014771-Ashton1" ref-type="bibr">[19]</xref> and the activity reaches a plateau at a relatively low Se
intake, similar to GPx1. Selenoprotein P is the main Se-containing protein in human
plasma, and is a reliable biomarker for Se-deficient populations, with a higher
plateau level than some of the glutathione peroxidases <xref rid="pone.0014771-Xia1" ref-type="bibr">[20]</xref>. Other less well studied
selenoproteins, such as selenoprotein W (SePW1), selenoprotein S (SePS1) and
selenoprotein R (SePR), are potential candidates as novel biomarkers. SePW1 and SePR
are reported to exhibit antioxidant activity <xref rid="pone.0014771-Jeong1" ref-type="bibr">[21]</xref>, <xref rid="pone.0014771-Kryukov2" ref-type="bibr">[22]</xref>; <italic>in vitro</italic>
over-expression of SePW1 in H1299 cells resulted in reduced susceptibility to
oxidative challenge by hydrogen peroxide <xref rid="pone.0014771-Jeong1" ref-type="bibr">[21]</xref>, and SePR catalyses
thioredoxin-dependent methionine-<italic>R-</italic> sulfoxide reduction <xref rid="pone.0014771-Kryukov2" ref-type="bibr">[22]</xref>. SePS1 has
been identified as a protein associated with the endoplasmic reticulum which
maintains lumen homeostasis by removal of misfolded proteins to the cytosol for
polyubiquitination and proteasomal degradation <xref rid="pone.0014771-Ye1" ref-type="bibr">[23]</xref>.</p><p>The aims of this study were to measure the expression of SEPS1, SEPR and SEPW1 after
supplementation with different forms and doses of Se, and the changes in response to
influenza vaccine (as an immune function challenge). The expression levels were
quantified and compared with &#x02018;classical&#x02019; biomarkers of Se status. This
is the first report of novel analysis of key Se-responsive genes in response to
supplements of Se-enriched yeast (Se-yeast) and Se-enriched onions, and the effect
of an immune function challenge using influenza vaccine.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>The protocol for this trial and supporting CONSORT checklist are available as
supporting information; see <xref ref-type="supplementary-material" rid="pone.0014771.s004">Checklist S1</xref> and <xref ref-type="supplementary-material" rid="pone.0014771.s003">Protocol
S1</xref>.</p><sec id="s2a"><title>Subjects and study design</title><p>A dietary intervention was undertaken, using a parallel design, in adults with
suboptimal Se status, defined by low plasma Se concentration (&#x0003c;110 ng/ml).
This study was part of a randomised, double-blind, placebo-controlled trial from
which the results for the use of plasma selenoprotein P as a biomarker have
previously been published <xref rid="pone.0014771-Hurst1" ref-type="bibr">[24]</xref>. Recruitment ran from May until the following
February in 2005, 2006 and 2007. This was related to the timing of the influenza
vaccine administration. For ethical and vaccine availability reasons the vaccine
had to be administered only during September to April; volunteers were therefore
recruited in May and began the study from July onwards to coincide with the
vaccination period. Recruitment stopped at the beginning of February each year
so that volunteers completed the study before the end of April. A pre-study
health screen was undertaken to assess basic blood chemistry and Se status in
each potential volunteer; the full list of exclusion criteria are given in Hurst
<italic>et al</italic>
<xref rid="pone.0014771-Hurst1" ref-type="bibr">[24]</xref>. A total
of 119 free-living, non-smoking men and women, aged 50&#x02013;64 y, completed the
study (<xref ref-type="supplementary-material" rid="pone.0014771.s001">Figure
S1</xref>). Each subject was randomly assigned to one of six groups and
given tablets containing either 50 (n&#x0200a;=&#x0200a;18), 100
(n&#x0200a;=&#x0200a;21) or 200 (n&#x0200a;=&#x0200a;23) &#x000b5;g
Se/day Se-yeast, meals made with Se-enriched onions containing 50 &#x000b5;g
Se/day (n&#x0200a;=&#x0200a;18) or unenriched onions
(n&#x0200a;=&#x0200a;17), or placebo tablets (n&#x0200a;=&#x0200a;20)
for a period of 12 weeks. For the allocation of volunteers, a computerised
random number generator was used (URL: <ext-link ext-link-type="uri" xlink:href="http://www.randomizer.org/form.htm">http://www.randomizer.org/form.htm</ext-link>). The tablets were provided
using a double blind design, as were the 2 onion groups. The double blind coding
was not revealed until the completion of the final data analysis. Volunteer
compliance to the interventions (for both the tablets and onion meal groups) was
monitored by self-administered tick sheets and in addition, for the supplement
groups by counting the number of tablets returned at the 6 and 12 week time
points. At week 10 the participants were vaccinated intra-muscularly with a
trivalent influenza vaccine, developed from World Health Organisation
guidelines. Blood samples (65 ml) were drawn from an antecubital vein in each
volunteer's forearm at week 0, 6 and 10 for pre-vaccination samples and at
week 11 and 12 for post-vaccination samples.</p></sec><sec id="s2b"><title>Platelet isolation and preparation of enzyme extracts</title><p>Platelets were isolated by centrifugation <xref rid="pone.0014771-Brown1" ref-type="bibr">[18]</xref> from 8 ml whole blood
collected in citrate coated polypropylene tubes (Sarstedt, Germany, <ext-link ext-link-type="uri" xlink:href="http://www.sarstedt.com">http://www.sarstedt.com</ext-link>) and were subsequently frozen in 0.32 M
sucrose solution, with controlled temperature gradient freezing to
&#x02212;80&#x000b0;C. When required for batch analysis of GPx1 and GPx4 activity,
enzyme extracts were prepared using ice-cold protein extraction cell lysis
buffer (100 mM Tris-HCl solution pH 7.4, 1 mM dithiothreitol DTT, 0.1&#x00025;
Triton X100 and protease inhibitor) and probe sonication with a sonicator
(Status 70, MS 72, Bandelin, Germany, <ext-link ext-link-type="uri" xlink:href="http://www.bandelin.com">http://www.bandelin.com</ext-link>).
Samples were maintained below 4&#x000b0;C during sonication, and then centrifuged at
12000g at 4&#x000b0;C for 10 min, the supernatants were stored on ice and GPx1
activity was quantified within 4 hours. Total protein concentrations were
determined using the method of Bradford <xref rid="pone.0014771-Bradford1" ref-type="bibr">[25]</xref> with HSA as a
standard.</p></sec><sec id="s2c"><title>Red blood cell isolation and preparation of enzyme extracts</title><p>Approximately 10 ml of whole blood was collected in a BD Vacutainer&#x02122; EDTA
tube (BD Medical, Cowley, UK, <ext-link ext-link-type="uri" xlink:href="http://www.bd.com/">http://www.bd.com/</ext-link>). After
centrifugation for 10 min at 1500 &#x000d7; g, 20&#x000b0;C the plasma layer and buffy
coat were removed and the remaining erythrocytes washed twice with ice-cold PBS.
Erythrocytes were diluted with one volume of ice-cold PBS and stored at
&#x02212;80&#x000b0;C. Enzyme extracts were prepared in batches from frozen
erythrocyte samples, were stored on ice and used within 4 hours for the
determination of Se dependent GPx1 activity. Haemoglobin (Hb) was quantified in
the erythrocyte enzyme extracts using the method described by Drabkin <xref rid="pone.0014771-Drabkin1" ref-type="bibr">[26]</xref>.</p></sec><sec id="s2d"><title>Se-dependent GPx1 activity in red blood cells and total GPx1 activity in
platelets</title><p>Glutathione peroxidase 1 activities in erythrocyte and platelet samples were
quantified using a spectrophotometric method <xref rid="pone.0014771-Paglia1" ref-type="bibr">[27]</xref>. The assay reaction mixture
contained 100 mM Tris-HCl pH 7.4, 3 mM glutathione, 0.25 mM NADPH, 1U
glutathione reductase and triton X100 (0.1&#x00025;). A high-throughput 96-well
enzyme assay <xref rid="pone.0014771-Smith1" ref-type="bibr">[28]</xref> was used to analyse samples and controls in
triplicate, with tert-butyl-hydroperoxide or cumene hydroperoxide as the
substrates for Se-dependent GPx1 activity or total GPx1 activity respectively
<xref rid="pone.0014771-Thomson2" ref-type="bibr">[29]</xref>. The
rate of decrease in absorbance at 340 nm was monitored at 37&#x000b0;C for 15 min
with measurements taken every 10 seconds. The GPx1 activity was calculated from
the initial rates of reaction as described by Paglia and Valentine <xref rid="pone.0014771-Paglia1" ref-type="bibr">[27]</xref>. One unit
(U) of glutathione peroxidase activity is defined as 1 &#x000b5;mol of NADPH
oxidised per minute.</p></sec><sec id="s2e"><title>GPx4 activity in platelets</title><p>Preparation of the reaction substrate 1-palmitoyl-2-(13-hydroperoxy-cis-9,
trans-11-octadecadienoyl)-l-3-phosphatidylcholine (PLPC-OOH) was as described by
Bao <italic>et al</italic>
<xref rid="pone.0014771-Bao1" ref-type="bibr">[30]</xref>. The assay
reaction mixture included 0.1 M Tris-HCl (pH 7.4), 2 mM EDTA, 1 mM sodium azide
(NaN<sub>3</sub>), 0.12&#x00025; Triton X-100, 3 mM glutathione and an
appropriate amount of platelet sample in 500 &#x000b5;l. The mixture was incubated
at 37&#x000b0;C for about 3 min and the reaction was started by the addition
PLPC-OOH to produce a final concentration of 25 &#x000b5;M. The reaction was
stopped by adding ice cold acetonitrile and then centrifuged at 12,000g at
4&#x000b0;C for 3 min to prepare for HPLC analysis. Separation of the product
(PLPC-OH) from the substrate (PLPC-OOH) was carried out using a Gemini 5 m C18
110A column (250&#x000d7;4.6 mm) (Phenomenex, Macclesfield, UK, <ext-link ext-link-type="uri" xlink:href="http://www.phenomenex.com">http://www.phenomenex.com</ext-link>) at 30&#x000b0;C. The mobile phase was a
mixture of acetonitrile-methanol-water (50:49.5:0.5, v/v/v) containing 10 mM
choline chloride. The flow rate was 0.5 ml/min and the UV detector wavelength
was set at 232 nm. GPx 4 activity was calculated from the PLPC-OOH and PLPC-OH
peaks as described <xref rid="pone.0014771-Bao1" ref-type="bibr">[30]</xref> and expressed per mg total protein.</p></sec><sec id="s2f"><title>Plasma Se</title><p>Approximately 10 ml whole blood was collected in sodium heparin trace element
free tubes (BD Medical, Cowley, UK). After centrifugation for 10 minutes at
1500g, 20&#x000b0;C the plasma was removed and stored at &#x02212;80&#x000b0;C in trace
element free tubes (BD Medical, Cowley, UK, <ext-link ext-link-type="uri" xlink:href="http://www.bd.com/">http://www.bd.com/</ext-link>). All samples
were analysed in duplicate in batches and a reference serum sample (Seronorm,
Norway, <ext-link ext-link-type="uri" xlink:href="http://www.sero.no/">http://www.sero.no/</ext-link>) was analysed and used as a quality control
check on each batch. Rhodium was added as an internal standard and Se
concentrations were determined using a 7500ce inductively coupled plasma mass
spectrometer (Agilent Technologies, Santa Clara, USA, <ext-link ext-link-type="uri" xlink:href="http://www.agilent.com/">http://www.agilent.com/</ext-link>) fitted with a dynamic reaction cell
operating in the hydrogen mode. Se was determined by monitoring at m/z 76, 77
and 78 for Se and m/z 103 for the rhodium internal standard against Se standards
of 0, 0.5, 1.0, 2.0, 5.0 and 10.0 ng/ml.</p></sec><sec id="s2g"><title>Peripheral blood mononuclear cell (PBMC) isolation and preparation of total
RNA for quantitative real time RT-PCR</title><p>Approximately 8 ml of whole blood was collected in a BD Vacutainer&#x02122;
CPT&#x02122; tube (BD Medical, Cowley, UK, <ext-link ext-link-type="uri" xlink:href="http://www.bd.com/">http://www.bd.com/</ext-link>). Blood
samples were processed within 30 min and PBMC's isolated according to the
manufacturer's instructions <xref rid="pone.0014771-Eady1" ref-type="bibr">[31]</xref>. Isolated PBMC's were lysed and homogenised
using a Qiashredder column and total RNA was then isolated using RNeasy mini kit
according to manufacturer's instructions (Qiagen, Crawley, UK, <ext-link ext-link-type="uri" xlink:href="http://www.qiagen.com">http://www.qiagen.com</ext-link>). RNA was eluted from the binding column
using 50 &#x000b5;l of RNase-free water. Ribonuclease inhibitor (Promega, Madison,
USA, <ext-link ext-link-type="uri" xlink:href="http://www.promega.com">http://www.promega.com</ext-link>) was added immediately (20 U/preparation)
and samples were stored at &#x02212;80&#x000b0;C. Total RNA yield was determined using
a NanoDrop ND-1000 spectrophotometer (Thermo Fischer Scientific, Breda,
Netherlands, <ext-link ext-link-type="uri" xlink:href="http://www.thermofisher.com">http://www.thermofisher.com</ext-link>) and purity assessed by the ratio of
absorbance at 260 and 280 nm.</p></sec><sec id="s2h"><title>Gene expression (SEPS1, SEPR, SEPW1) using quantitative real time
RT-PCR</title><p>Determination of mRNA levels was performed by quantitative real-time reverse
transcription-PCR (RT-PCR) using ABI Prism 7300 Sequence Detection System
(Applied Biosystems, Warrington,UK, <ext-link ext-link-type="uri" xlink:href="http://www.appliedbiosystems.com">http://www.appliedbiosystems.com</ext-link>). Primers and fluorogenic
probes (5&#x02032; FAM- 3&#x02032; TAMRA) were designed across exon-exon boundaries
using Primer Express Software (Operon, Cologne, Germany, <ext-link ext-link-type="uri" xlink:href="http://www.operon.com/">http://www.operon.com/</ext-link>) (<xref ref-type="table" rid="pone-0014771-t001">Table 1</xref>). Oligomer specificity was checked
using NCBI BLAST (<ext-link ext-link-type="uri" xlink:href="http://blast.ncbi.nlm.nih.gov/Blast.cgi">http://blast.ncbi.nlm.nih.gov/Blast.cgi</ext-link>) searches to confirm no
sequence homologies with unrelated targets. Amplification products for each
primer and probe set were run on 10&#x00025; TBE Novex gels (Invitrogen, Paisley,
UK, <ext-link ext-link-type="uri" xlink:href="http://www.invitrogen.com">http://www.invitrogen.com</ext-link>) to verify the sizes of the resulting
amplicons. RT-PCR reactions were performed in 96 well plates using TaqMan
one-step RT-PCR master mix reagent kit (Applied Biosystems, Warrington,UK,
<ext-link ext-link-type="uri" xlink:href="http://www.appliedbiosystems.com">http://www.appliedbiosystems.com</ext-link>) in a total volume of 25
&#x000b5;l/well consisting of 100&#x02013;200 nM probe, 200&#x02013;400 nM forward and
reverse primers and 10 ng RNA. TaqMan RT-PCR conditions were as follows:
48&#x000b0;C for 30 min, 95&#x000b0;C for 10 min then 40 cycles of 95&#x000b0;C for 15 s and
60&#x000b0;C for 1 min. Gene expression was quantified using the relative standard
curve method <xref rid="pone.0014771-Applied1" ref-type="bibr">[32]</xref>. A master stock of total RNA was extracted from the
pooled blood of 3 individuals. Standard curves using the master RNA stock were
included on every plate, each time using triplicate replicates for each amount.
The range of the standard curve encompassed the observed range of sample values.
<italic>&#x003b2;</italic>-glucuronidase (GUSB) was measured as a reference gene
<xref rid="pone.0014771-Vandesompele1" ref-type="bibr">[33]</xref>, <xref rid="pone.0014771-Loseke1" ref-type="bibr">[34]</xref> (<xref ref-type="table" rid="pone-0014771-t001">Table
1</xref>).</p><table-wrap id="pone-0014771-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0014771.t001</object-id><label>Table 1</label><caption><title>Primer and probe sequences used for real-time reverse transcription
PCR reactions.</title></caption><alternatives><graphic id="pone-0014771-t001-1" xlink:href="pone.0014771.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">GeneAccesssion No.</td><td align="left" rowspan="1" colspan="1">Sequence (5&#x02032;-3&#x02032;)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>SEPW1</bold>
</td><td align="left" rowspan="1" colspan="1">Forward primer <named-content content-type="gene">AGGCCACCGGGTTCTTTG</named-content>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_003009</td><td align="left" rowspan="1" colspan="1">Reverse primer <named-content content-type="gene">CGTAGCCATCGCCTTTCTTC</named-content>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Probe
<italic>FAM</italic>-AGAGTGAATCAACTTCCCGGCTACCATCA-<italic>TAMRA</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SEPS1</bold>
</td><td align="left" rowspan="1" colspan="1">Forward primer <named-content content-type="gene">AGCCCCAGGAGGAAGACAGT</named-content>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_018445</td><td align="left" rowspan="1" colspan="1">Reverse primer <named-content content-type="gene">TCCCCGCAAAGGCTTTCT</named-content>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Probe
<italic>FAM</italic>-ACTTCATCTGTCCTGAAACGGAAATCGGA-<italic>TAMRA</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SEPR</bold>
</td><td align="left" rowspan="1" colspan="1">Forward primer <named-content content-type="gene">GCGTCCGGAGCACAATAGAT</named-content>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_016332</td><td align="left" rowspan="1" colspan="1">Reverse primer <named-content content-type="gene">TGGCCCAACCCATTGC</named-content>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Probe <named-content content-type="gene">
<italic>FAM-</italic>CACAGGACACCTTCAAGGCTTCA-<italic>TAMRA</italic>
</named-content>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>GUS</bold>
</td><td align="left" rowspan="1" colspan="1">Forward primer <named-content content-type="gene">TTGGCAGTGCCCATTCCT</named-content>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NM_000181</td><td align="left" rowspan="1" colspan="1">Reverse primer <named-content content-type="gene">GTAGCCCCCCTCATGCTCTAG</named-content>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Probe <named-content content-type="gene">
<italic>FAM</italic>-CCCATTCACCCACACGATGGCA-<italic>TAMRA</italic>
</named-content>
</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s2i"><title>Ethics</title><p>Governance and ethical approvals for this study were obtained from the Institute
of Food Research Governance Committee, the East Norfolk and Waveney Research
Governance Committee and the Norwich Local Ethics Committee (<xref ref-type="supplementary-material" rid="pone.0014771.s002">Text S1</xref>).
Written informed consent was obtained from each participant.<bold/>
</p></sec><sec id="s2j"><title>Statistics</title><p>The primary endpoints of the study were changes in gene expression of SEPS1,
SEPW1 and SEPR in response to dietary Se supplementation comparing baseline
values with those at weeks 6, 10, 11 and 12. The secondary endpoints were
changes in SEPS1, SEPW1 and SEPR between vaccine administration at week 10 to
weeks one and two post-vaccination (weeks 11 and 12). Statistical analyses were
performed using the R data analysis software <xref rid="pone.0014771-R1" ref-type="bibr">[35]</xref>. Standard ANOVA models and
mixed-effects models were employed to analyse these data. The main effects
tested in the models were supplementation group and time; interactions of these
terms were also tested. For all models, diagnostics were checked to determine if
data transformations, outlier omissions, or alternative non-parametric models
were required. All results from the models were considered significant if
P&#x0003c;0.05. When a factor in an ANOVA was significant, a Tukey's honest
significant difference post-hoc test was applied. When a factor in the
mixed-effects models showed a significant effect, contrasts between levels in
the factor were used to estimate whether the pairwise differences were
significant. Adjustments for multiple testing were made for all post-hoc
tests.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Blood analysis</title><p>Red cell count, white cell count, Hb, haematocrit, mean cell Hb and platelet
count did not significantly change over the duration of the intervention. The
mean red blood cell count was 4.6&#x000b1;0.48&#x000d7;10<sup>12</sup>/ L and
ranged from 1.06 to 6.07&#x000d7;10<sup>12</sup>/ L, White blood cell counts were
5.3&#x000b1;1.3&#x000d7;10<sup>9</sup>/ L and ranged from 2.5&#x02013;10.6), Hb
(mean: 14.0&#x000b1;1.1 g/dL, range: 11.7&#x02013;19.7), haematocrit (mean:
41&#x000b1;3&#x00025; range: 34&#x02013;51&#x00025;), mean cell Hb
(mean:30.6&#x000b1;2.5 pg range:12.1&#x02013;58.7) and platelet count
(mean:254&#x000b1;56&#x000d7;10<sup>9</sup>/ L range: 138&#x02013;463).</p></sec><sec id="s3b"><title>Effect of Se supplementation on Se-dependent GPx1 activity in red blood cells
and total GPx1 activity in platelets</title><p>Se-dependent GPx1 activity was quantified in erythrocyte samples at week 0 and
12, the mean activities are displayed in <xref ref-type="table" rid="pone-0014771-t002">Table 2</xref>. A significant effect of time was
identified by ANOVA analysis for the erythrocyte GPx1 activity in the Se-yeast
groups. Post-hoc analysis revealed a significantly greater erythrocyte GPx1
activity at week 12 compared to baseline week 0 (P&#x0003c;0.001). However, there
were no significant effects of Se-yeast dose or Se-enriched onions on
erythrocyte GPx1 activity compared to the placebo and unenriched onion groups
respectively. There were also no significant differences in total GPx1 activity
in platelets in the Se supplemented groups compared with the control groups.
Over the duration of the intervention, time was found to have a significant
effect on platelet total GPx1 activity. Post-hoc analysis showed this to be due
to an increase in activity in only the 100 &#x000b5;g/day Se-yeast group at week
12 compared with baseline, week 0 (P&#x0003c;0.001). There were no significant
effects of the influenza vaccine on platelet total GPx1 activity, week 10
compared with week 12 data, for any of the groups.</p><table-wrap id="pone-0014771-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0014771.t002</object-id><label>Table 2</label><caption><title>Se-dependent glutathione peroxidase 1 activity in erythrocytes, total
glutathione peroxidase 1 and Se-dependent glutathione peroxidase 4
activities in platelets: mean values at 0, 6, 10 and 12 weeks of
supplementation and comparison of Se-yeast and Se-enriched onion meals
with the placebo and unenriched onion groups respectively<xref ref-type="table-fn" rid="nt101">1</xref>.</title></caption><alternatives><graphic id="pone-0014771-t002-2" xlink:href="pone.0014771.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Se-dependent glutathione peroxidase 1
activity in erythrocytes (&#x000b5;mol/min per g Hb)</td><td colspan="4" align="left" rowspan="1">Total glutathione peroxidase 1 activity
in platelets (&#x000b5;mol/ min per mg protein)</td><td colspan="4" align="left" rowspan="1">Se-dependent glutathione peroxidase 4
activity in platelets (&#x000b5;mol/min per mg protein)<xref ref-type="table-fn" rid="nt102">2</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Time (weeks)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">12</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Placebo (n&#x0200a;=&#x0200a;20)</td><td align="left" rowspan="1" colspan="1">44.2&#x000b1;12.1 (34.4&#x02013;82.9)</td><td align="left" rowspan="1" colspan="1">47.8&#x000b1;11.3 (32.8&#x02013;75.7)</td><td align="left" rowspan="1" colspan="1">0.28&#x000b1;0.08 (0.13&#x02013;.39)</td><td align="left" rowspan="1" colspan="1">0.29&#x000b1;0.11 (0.15&#x02013;0.53)</td><td align="left" rowspan="1" colspan="1">0.26&#x000b1;0.09 (0.11&#x02013;0.41)</td><td align="left" rowspan="1" colspan="1">0.29&#x000b1;0.07 (0.09&#x02013;0.40)</td><td align="left" rowspan="1" colspan="1">8.6&#x000b1;5.0 (3.0&#x02013;19.1)</td><td align="left" rowspan="1" colspan="1">11.1&#x000b1;8.4 (2.5&#x02013;31.9)</td><td align="left" rowspan="1" colspan="1">9.1&#x000b1;4.6 (4.1&#x02013;18.0)</td><td align="left" rowspan="1" colspan="1">9.4&#x000b1;6.4 (2.9&#x02013;15.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">50 &#x000b5;g/day Se-yeast
(n&#x0200a;=&#x0200a;18)</td><td align="left" rowspan="1" colspan="1">49.6&#x000b1;10.3 (34.4&#x02013;65.2)</td><td align="left" rowspan="1" colspan="1">53.0&#x000b1;13.7 (35.0&#x02013;78.9)</td><td align="left" rowspan="1" colspan="1">0.29&#x000b1;0.13 (0.16&#x02013;0.44)</td><td align="left" rowspan="1" colspan="1">0.32&#x000b1;0.16 (0.15&#x02013;0.64)</td><td align="left" rowspan="1" colspan="1">0.29&#x000b1;0.13 (0.15&#x02013;0.49)</td><td align="left" rowspan="1" colspan="1">0.34&#x000b1;0.16 (0.12&#x02013;0.72)</td><td align="left" rowspan="1" colspan="1">9.1&#x000b1;6.5 (2.5&#x02013;24.1)</td><td align="left" rowspan="1" colspan="1">11.3&#x000b1;7.0 (3.3&#x02013;29.2)</td><td align="left" rowspan="1" colspan="1">12.3&#x000b1;6.5 (5.3&#x02013;23.1)</td><td align="left" rowspan="1" colspan="1">10.6&#x000b1;6.5 (2.5&#x02013;24.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">100 &#x000b5;g/day Se-yeast
(n&#x0200a;=&#x0200a;21)</td><td align="left" rowspan="1" colspan="1">46.3&#x000b1;11.7 (26.6&#x02013;74.1)</td><td align="left" rowspan="1" colspan="1">48.4&#x000b1;14.1 (24.5&#x02013;82.2)</td><td align="left" rowspan="1" colspan="1">0.25&#x000b1;0.13 (0.10&#x02013;0.52)</td><td align="left" rowspan="1" colspan="1">0.28&#x000b1;0.12 (0.14&#x02013;0.59)</td><td align="left" rowspan="1" colspan="1">0.27&#x000b1;0.14 (0.14&#x02013;0.57)</td><td align="left" rowspan="1" colspan="1">0.34&#x000b1;0.15&#x0002a;&#x0002a; (0.23&#x02013;0.68)</td><td align="left" rowspan="1" colspan="1">8.4&#x000b1;3.9 (2.7&#x02013;15.6)</td><td align="left" rowspan="1" colspan="1">12.0&#x000b1;9.4 (2.6&#x02013;36.8)</td><td align="left" rowspan="1" colspan="1">10.9&#x000b1;5.8 (3.4&#x02013;18.7)</td><td align="left" rowspan="1" colspan="1">11.8&#x000b1;7.1&#x0002a; (5.0&#x02013;26.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">200 &#x000b5;g/day Se-yeast
(n&#x0200a;=&#x0200a;23)</td><td align="left" rowspan="1" colspan="1">47.9&#x000b1;15.2 (27.1&#x02013;76.1)</td><td align="left" rowspan="1" colspan="1">49.8&#x000b1;16.2 (28.4&#x02013;83.2)</td><td align="left" rowspan="1" colspan="1">0.26&#x000b1;0.08 (0.11&#x02013;0.40)</td><td align="left" rowspan="1" colspan="1">0.29&#x000b1;0.11 (0.16&#x02013;0.58)</td><td align="left" rowspan="1" colspan="1">0.29&#x000b1;0.10 (0.17&#x02013;0.50)</td><td align="left" rowspan="1" colspan="1">0.29&#x000b1;0.09 (0.17&#x02013;0.51)</td><td align="left" rowspan="1" colspan="1">10.8&#x000b1;6.8 (2.5&#x02013;19.1)</td><td align="left" rowspan="1" colspan="1">11.5&#x000b1;6.2 (0.4&#x02013;22.0)</td><td align="left" rowspan="1" colspan="1">12.4&#x000b1;7.6 (3.4&#x02013;30.7)</td><td align="left" rowspan="1" colspan="1">12.8&#x000b1;7.6 (2.5&#x02013;28.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Unenriched onions
(n&#x0200a;=&#x0200a;17)</td><td align="left" rowspan="1" colspan="1">42.6&#x000b1;10.9 (19.7&#x02013;63.7)</td><td align="left" rowspan="1" colspan="1">43.0&#x000b1;11.5 (19.9&#x02013;64.7)</td><td align="left" rowspan="1" colspan="1">0.31&#x000b1;0.10 (0.12&#x02013;0.50)</td><td align="left" rowspan="1" colspan="1">0.31&#x000b1;0.11 (0.13&#x02013;0.49)</td><td align="left" rowspan="1" colspan="1">0.31&#x000b1;0.09 (0.15&#x02013;0.48)</td><td align="left" rowspan="1" colspan="1">0.35&#x000b1;0.15 (0.18&#x02013;0.67)</td><td align="left" rowspan="1" colspan="1">10.5&#x000b1;5.7 (3.6&#x02013;23.2)</td><td align="left" rowspan="1" colspan="1">13.0&#x000b1;9.6 (6.0&#x02013;44.5)</td><td align="left" rowspan="1" colspan="1">11.8&#x000b1;4.0 (6.6&#x02013;20.2)</td><td align="left" rowspan="1" colspan="1">11.0&#x000b1;5.0 (1.4&#x02013;19.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Se-enriched onions 50 &#x000b5;g/day
(n&#x0200a;=&#x0200a;18)</td><td align="left" rowspan="1" colspan="1">49.4&#x000b1;16.5 (24.0&#x02013;87.3)</td><td align="left" rowspan="1" colspan="1">55.6&#x000b1;21.6 (24.3&#x02013;106.4)</td><td align="left" rowspan="1" colspan="1">0.33&#x000b1;0.12 (0.18&#x02013;0.54)</td><td align="left" rowspan="1" colspan="1">0.35&#x000b1;0.14 (0.16&#x02013;0.59)</td><td align="left" rowspan="1" colspan="1">0.33&#x000b1;0.12 (0.09&#x02013;0.50)</td><td align="left" rowspan="1" colspan="1">0.35&#x000b1;0.13 (0.15&#x02013;0.67)</td><td align="left" rowspan="1" colspan="1">5.4&#x000b1;3.9 (0.4&#x02013;13.1)</td><td align="left" rowspan="1" colspan="1">7.6&#x000b1;7.7 (0.8&#x02013;26.4)</td><td align="left" rowspan="1" colspan="1">6.5&#x000b1;5.1<sup>#</sup> (0.7&#x02013;17.0)</td><td align="left" rowspan="1" colspan="1">7.0&#x000b1;6.7 (1.6&#x02013;23.7)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>
<sup><italic>1</italic></sup>All values are means &#x000b1; SDs;
ranges in parentheses. Se-dependent activities in erythrocyte
samples were determined using tert-butyl hydroperoxide as the
substrate in the enzyme assay. Total GPx activities in platelet
samples were determined using cumene hydroperoxide as the substrate
in the enzyme assay <xref rid="pone.0014771-Paglia1" ref-type="bibr">[27]</xref>, <xref rid="pone.0014771-Thomson2" ref-type="bibr">[29]</xref>.</p></fn><fn id="nt102"><label/><p>
<sup><italic>2</italic></sup>numbers (n) for the GPx4 data are as
detailed in the text; placebo (n&#x0200a;=&#x0200a;11), 50, 100
and 200 &#x000b5;g/day (n&#x0200a;=&#x0200a;12, 14 and 19
respectively), unenriched (n&#x0200a;=&#x0200a;14) and
Se-enriched (n&#x0200a;=&#x0200a;9) due to undetectable GPx4
activity in the platelet enzyme extract compared with the control
enzyme extraction buffer. &#x0002a; P&#x0003c;0.05 for the comparison of
Time&#x0200a;=&#x0200a;12 to Time&#x0200a;=&#x0200a;0;
&#x0002a;&#x0002a; P&#x0003c;0.005 for the comparison of
Time&#x0200a;=&#x0200a;12 to Time&#x0200a;=&#x0200a;0; #
P&#x0003c;0.005 for the comparison with unenriched onion.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Effect of Se supplementation on GPx4 activity in platelets</title><p>The effects of the intervention on GPx4 activity are shown in <xref ref-type="table" rid="pone-0014771-t002">Table 2</xref>. No significant
differences were observed when comparing the Se-yeast groups with placebo group
with respect to GPx4 activity. Overall, the Se-enriched onion group had lower
GPx4 activity compared with the control unenriched onion group, which was
largely attributed to the significantly lower (P&#x0003c;0.005) GPx4 activity at week
10 in the Se-enriched onion group than that of the unenriched onion group. It
should be noted that some data are missing for samples where the activity of the
enzyme extract in the platelet sample was less than the control enzyme
extraction buffer which resulted in fewer data points in each of the groups
(placebo n&#x0200a;=&#x0200a;11; 50 &#x000b5;g/day Se-yeast
n&#x0200a;=&#x0200a;12; 100 &#x000b5;g/day Se-yeast
n&#x0200a;=&#x0200a;14; 200 &#x000b5;g/day Se-yeast
n&#x0200a;=&#x0200a;19; control unenriched onion
n&#x0200a;=&#x0200a;14; 50 &#x000b5;g/day Se-enriched onion
n&#x0200a;=&#x0200a;9). A significant effect of time on GPx4 activity was
identified using ANOVA and post-hoc analysis showed a statistically significant
(P&#x0003c;0.05) increase in platelet GPx4 activity at week 12 compared with week 0
only for the group that received 100 &#x000b5;g/day Se-yeast (<xref ref-type="table" rid="pone-0014771-t002">Table 2</xref>). There were no
significant effects of the influenza vaccine on platelet GPx4 activity, week 10
compared with week 12 data, for any of the groups.</p></sec><sec id="s3d"><title>Plasma Se</title><p>Plasma Se concentration increased significantly in the Se-yeast groups compared
to the placebo group up to week 10 as reported previously <xref rid="pone.0014771-Hurst1" ref-type="bibr">[24]</xref>. Previously unreported data
(plasma Se concentration 1 and 2 weeks following influenza vaccination) show no
significant change in any of the groups (<xref ref-type="fig" rid="pone-0014771-g001">Figure 1</xref>) which indicates that the volunteers
had reached steady state Se status by week 10 and that the administration of
influenza vaccine had no significant effect on plasma Se concentration.</p><fig id="pone-0014771-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0014771.g001</object-id><label>Figure 1</label><caption><title>Plasma Se concentration over the 12 week intervention period for all
groups.</title><p>Values are means &#x000b1; SEM. &#x025a1; Placebo
(n&#x0200a;=&#x0200a;20); &#x025aa; 50 &#x000b5;g/day Se-yeast
(n&#x0200a;=&#x0200a;17); &#x02666; 100 &#x000b5;g/day Se-yeast
(n&#x0200a;=&#x0200a;21); &#x000d7;200 &#x000b5;g/day Se-yeast
(n&#x0200a;=&#x0200a;23); &#x025cb; Unenriched onions
(n&#x0200a;=&#x0200a;16); &#x02022; 50 &#x000b5;g/day Se-enriched onion
meals (n&#x0200a;=&#x0200a;18). &#x025b4; denotes influenza vaccine
challenge administered at week 10 of the study. Plasma Se concentration
data displayed for weeks 11 and 12, one and two weeks post-vaccination,
are novel data. To display the effect of Se supplementation over the
duration of the intervention period and to illustrate the plasma Se
concentration before and after vaccination, data from time points
baseline, week 6 and 10 are reproduced with permission of Hurst
<italic>et al</italic>. 2010 <xref rid="pone.0014771-Hurst1" ref-type="bibr">[24]</xref>.</p></caption><graphic xlink:href="pone.0014771.g001"/></fig></sec><sec id="s3e"><title>SEPW1, SEPR and SEPS1 gene expression in response to Se supplementation and
effect of influenza vaccine challenge</title><p>A significant treatment effect of Se-enriched yeast on PBMC SEPW1 mRNA level was
identified at week 10. The SEPW1 mRNA levels were 25&#x00025; lower in the 200
&#x000b5;g/day Se-yeast group compared with the placebo group at this time point
(p&#x0200a;=&#x0200a;0.007) (<xref ref-type="fig" rid="pone-0014771-g002">Figure 2</xref>). The SEPW1 mRNA level of the placebo group and the lower
dose Se-yeast groups (50 or 100 &#x000b5;g/day) did not change significantly at
weeks 6, 10, 11 or 12. The reduction at week 10 in SEPW1 mRNA levels was
negatively correlated with plasma Se concentration
(P&#x0200a;=&#x0200a;0.022); a negative trend was also observed at the
majority of the sampling points of the intervention period (<xref ref-type="fig" rid="pone-0014771-g002">Figure 2</xref>). No significant differences were
found in the levels of SEPR mRNA when comparing the Se-yeast to placebo groups
at each sampling point or between supplement groups over the course of the
intervention (<xref ref-type="fig" rid="pone-0014771-g002">Figure 2</xref>).
Inter-individual variation was 40&#x00025; greater for this marker than for SEPS1
or SEPW1.</p><fig id="pone-0014771-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0014771.g002</object-id><label>Figure 2</label><caption><title>mRNA level in PBMCs measured over the duration of intervention period
for (A) SEPW1, (B) SEPS1, (C) SEPR in the placebo and Se-yeast
groups.</title><p>Values are means &#x000b1; SEM relative to baseline, week 0 expression.
GUSB was used as reference gene for normalisation. White bars
&#x0200a;=&#x0200a; placebo group (n&#x0200a;=&#x0200a;14 to
20); light grey bars &#x0200a;=&#x0200a; 50 &#x000b5;g/day Se-yeast
(n&#x0200a;=&#x0200a;11 to 15); mid grey bars
&#x0200a;=&#x0200a; 100 &#x000b5;g/day Se-yeast
(n&#x0200a;=&#x0200a;10 to 19); black bars &#x0200a;=&#x0200a;
200 &#x000b5;g/day Se-yeast (n&#x0200a;=&#x0200a;14 to 18). The
variation in sample number (n) between time points for each treatment is
due to insufficient RNA at some sampling time points and missing time
course sample data for some of the target genes. For the SEPS1 gene
expression data set: placebo group n&#x0200a;=&#x0200a;20 at all
time points; 50 &#x000b5;g/day group n&#x0200a;=&#x0200a;14 at wks 0,
6 and 12 (n&#x0200a;=&#x0200a;13 at wks 10, 11); 100 &#x000b5;g/day
group n&#x0200a;=&#x0200a;19 at wks 0, 6, 10
(n&#x0200a;=&#x0200a;18 at wks 11, 12); 200 &#x000b5;g/day group
n&#x0200a;=&#x0200a;18 at wks 0, 6, 12 (n&#x0200a;=&#x0200a;17
wk 10, n&#x0200a;=&#x0200a;15 wk 11). Data were analysed using
mixed-effects models and statistically significant differences are
indicated on the figure.</p></caption><graphic xlink:href="pone.0014771.g002"/></fig><p>SEPS1 was significantly up-regulated 7 days after the influenza vaccine challenge
at week 10 (P&#x0200a;=&#x0200a;0.003) (<xref ref-type="fig" rid="pone-0014771-g003">Figure 3</xref>). At Week 11 SEPS1 mRNA levels
demonstrated a positive Se dose-dependent correlation
(P&#x0200a;=&#x0200a;0.009). The SEPS1 mRNA levels in the 200 &#x000b5;g
Se-yeast group were on average 16&#x00025; higher than those of the placebo or 50
&#x000b5;g Se-yeast group and 10&#x00025; greater than the 100 &#x000b5;g Se-yeast
group (<xref ref-type="fig" rid="pone-0014771-g002">Figure 2</xref>). A
significant effect of time on SEPS1 mRNA level was identified using ANOVA.
Post-hoc testing found that SEPS1 mRNA increased
(P&#x0200a;=&#x0200a;0.007) one week after the influenza vaccine (week 11)
compared to pre-vaccination (week 10) in the 100 &#x000b5;g/day Se-yeast group and
there was a similar increase in the 200 &#x000b5;g/day Se-yeast group, which was
of borderline significance (P&#x0200a;=&#x0200a;0.055). SEPS1 mRNA did not
change in the placebo group and the 50 &#x000b5;g/day Se-yeast group at week 11
compared to week 10. Two weeks after the influenza vaccination (week 12) SEPS1
mRNA fell to levels comparable with those at week 10 (pre-vaccination).</p><fig id="pone-0014771-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0014771.g003</object-id><label>Figure 3</label><caption><title>SEPS1 mRNA level in PMBCs measured over the intervention period, each
time point showing the mean of all the yeast supplement groups (placebo,
50, 100 and 200 &#x000b5;g/day).</title><p>GUSB was used as reference gene for normalisation. Data are presented as
mean &#x000b1; SEM (n&#x0200a;=&#x0200a;65 to 71 per time point)
relative to baseline, week 0 expression.</p></caption><graphic xlink:href="pone.0014771.g003"/></fig><p>When the gene expression profiles of SEPS1, SEPW1 and SEPR in the PBMC samples
from volunteers in the Se-enriched onion group are compared with the unenriched
onion group, there was a consistent trend with mean mRNA levels of SEPW1, SEPS1
and SEPR being higher in the Se-enriched onion group (<xref ref-type="fig" rid="pone-0014771-g004">Figure 4</xref>). There was a significant treatment
effect on SEPW1 mRNA, with higher levels in the Se-enriched onion group
(P&#x0200a;=&#x0200a;0.012) compared to the unenriched onion group. There
was also an increase in SEPS1 mRNA levels in the Se-enriched onion group
compared with the unenriched onion group, but this was only borderline
significant (P&#x0200a;=&#x0200a;0.059). SEPS1 mRNA levels were
significantly influenced by time (P&#x0200a;=&#x0200a;0.009) which was
largely due to the increase in expression at week 11, one week post-vaccination.
Differences in gene expression of SEPR when comparing the Se-enriched onion
group with the unenriched onion group showed a similar pattern of expression to
that of SEPS1 but the changes in SEPR over time and comparing treatments were
not significant due to the relatively small average fold change in expression
between the groups and also due to large inter-individual variation in gene
expression/mRNA level.</p><fig id="pone-0014771-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0014771.g004</object-id><label>Figure 4</label><caption><title>SEPW1, SEPS1 and SEPR mRNA level over the duration of the
intervention in the PBMC samples from the unenriched and Se-enriched
onion meal groups.</title><p>SEPW1, SEPS1 and SEPR mRNA levels were quantified using real time RT-PCR
and normalised to reference gene, GUSB. Data expressed are means
&#x000b1; SEM relative to baseline, week 0 expression. (A) SEPW1, (B)
SEPS1, (C) SEPR. Values are means &#x000b1; SEM. ---&#x025cb;--- unenriched
onions, n&#x0200a;=&#x0200a;14 to 16;&#x02014;&#x02022;&#x02014;
Se-enriched onions, n&#x0200a;=&#x0200a;16 to 17. SEPW1 mRNA level
is significantly greater in the enriched onion group compared to the
unenriched onion group (p&#x0200a;=&#x0200a;0.012). SEPS1 mRNA
level is significantly influenced by week
(p&#x0200a;=&#x0200a;0.009).</p></caption><graphic xlink:href="pone.0014771.g004"/></fig><p>The main finding of this study was the up-regulation of SEPS1 mRNA in response to
influenza vaccine, with a dose-dependent relationship between the magnitude of
increase in SEPS1 gene expression and the level of Se supplementation.</p></sec></sec><sec id="s4"><title>Discussion</title><p>The ranges in GPx1 and GPx4 activities in erythrocytes and platelets in this study
were similar to values observed in another UK cohort <xref rid="pone.0014771-Brown1" ref-type="bibr">[18]</xref>. It has been reported that
platelet GPx1 and GPx4 activities reflect Se status more accurately than other blood
Se biomarkers <xref rid="pone.0014771-Brown1" ref-type="bibr">[18]</xref>,
<xref rid="pone.0014771-Thomson3" ref-type="bibr">[36]</xref>-<xref rid="pone.0014771-Neve2" ref-type="bibr">[38]</xref>, however, the
response of GPx1 activity reaches a plateau at approx 80&#x02013;100 ng/ml plasma Se
<xref rid="pone.0014771-Thomson1" ref-type="bibr">[10]</xref>, <xref rid="pone.0014771-Neve1" ref-type="bibr">[12]</xref>, <xref rid="pone.0014771-Thomson3" ref-type="bibr">[36]</xref> and so the use
of platelet GPx activity as a biomarker of status is restricted to Se- deficient
populations. No significant differences in the Se-dependent GPx1 activity in
platelets in this cohort were reported previously <xref rid="pone.0014771-Hurst1" ref-type="bibr">[24]</xref>. In this study total GPx1
activity in platelets (short-term marker of status) was analysed using a different
substrate (cumene hydroperoxide) for the enzyme activity quantification <xref rid="pone.0014771-Thomson2" ref-type="bibr">[29]</xref>, compared to
the data previously published <xref rid="pone.0014771-Hurst1" ref-type="bibr">[24]</xref>, plus analysis of erythrocyte GPx1 as a long-term marker
of Se status <xref rid="pone.0014771-Thomson1" ref-type="bibr">[10]</xref>
was completed. Platelet Se-dependent GPx4 activity was also quantified to ascertain
whether a further array of relevant antioxidant enzyme activities in blood cells
would reflect Se status in this study population. Although there were significant
changes in platelet total GPx1 and Se-dependent GPx4 activities in platelet samples
from the 100 &#x000b5;g/day Se-yeast group at week 12 compared to baseline, none of
the four Se supplemented groups showed significant increases in total GPx activity
over the duration of the intervention compared to the placebo group, most probably
because the majority of volunteers had habitual Se intakes associated with maximal
GPx activity (the plasma Se concentration at baseline was 95.7&#x000b1;1.5 ng/ml).
Total GPx1 activity in platelets and Se-dependent GPx1 activity in erythrocytes were
not sensitive biomarkers of Se status within the range of this intervention study.
This was also the case with GPx4, as GPx4 activity may plateau over a similar range.
Furthermore, the small but not significant increases in GPx4 over time, when
compared to baseline week 0, (observed in the 50 and 200 &#x000b5;g/day Se-yeast and
Se-enriched onion groups), may be related to the form of Se used in this
intervention as sodium selenite supplements of 100 &#x000b5;g /day resulted in a
significant increase in GPx4 activity in lymphocytes in another UK cohort <xref rid="pone.0014771-Broome1" ref-type="bibr">[8]</xref>.</p><p>Between 10&#x02013;30&#x00025; of Se in plasma is found in GPx <xref rid="pone.0014771-Burk2" ref-type="bibr">[13]</xref>, <xref rid="pone.0014771-Deagen1" ref-type="bibr">[39]</xref> and approximately
25&#x02013;50&#x00025; in selenoprotein P <xref rid="pone.0014771-Burk2" ref-type="bibr">[13]</xref>, <xref rid="pone.0014771-Deagen1" ref-type="bibr">[39]</xref>, <xref rid="pone.0014771-Akesson1" ref-type="bibr">[40]</xref>. There is also a proportion of
Se bound to albumin <xref rid="pone.0014771-Burk2" ref-type="bibr">[13]</xref>, <xref rid="pone.0014771-Deagen1" ref-type="bibr">[39]</xref>, and &#x02018;unknown&#x02019; selenoproteins and small Se
metabolites account for the remaining plasma Se <xref rid="pone.0014771-Burk2" ref-type="bibr">[13]</xref>. Total plasma Se and
selenoprotein P concentrations are good markers of Se status <xref rid="pone.0014771-Ashton1" ref-type="bibr">[19]</xref>, <xref rid="pone.0014771-Hurst1" ref-type="bibr">[24]</xref>, but plasma Se does not reflect
the intake of all forms of Se <xref rid="pone.0014771-Hurst1" ref-type="bibr">[24]</xref>. The results presented in this paper show that the
steady-state plasma Se concentrations achieved in the different intervention groups
were not significantly changed by influenza vaccine administration.</p><p>Molecular assays are increasingly used to assess disease and health status and may be
useful for the evaluation of nutritional status <xref rid="pone.0014771-Arab1" ref-type="bibr">[41]</xref>, <xref rid="pone.0014771-Kussmann1" ref-type="bibr">[42]</xref>. A number of studies using
animal models have successfully used molecular markers to identify significant
differences between groups deprived of dietary Se and those with adequate Se diets
<xref rid="pone.0014771-Kipp1" ref-type="bibr">[43]</xref>-<xref rid="pone.0014771-Pagmantidis1" ref-type="bibr">[46]</xref>. A
comparison of tissue mRNA levels in Se-deficient compared to Se-replete rats
reported reductions of both thioredoxin reductase and SEPW1 mRNA by up to 70&#x00025;
in Se deficiency <xref rid="pone.0014771-Hadley1" ref-type="bibr">[45]</xref>, <xref rid="pone.0014771-Pagmantidis1" ref-type="bibr">[46]</xref>. The <italic>in vitro</italic> expression of SEPW1 mRNA
in human colon cells increased by 3.7 fold in cells cultured in media supplemented
with sodium selenite compared to media containing sub- optimal Se content <xref rid="pone.0014771-Pagmantidis1" ref-type="bibr">[46]</xref>. The data
presented here do not, however, reflect the magnitude of change in molecular markers
of Se status that is observed in animal or <italic>in vitro</italic> models. This is
likely due to higher inter-individual variability in human subjects and may also
reflect the tight regulation of selenogene and selenoprotein expression. In
addition, the level of Se deficiency routinely used in animal studies <xref rid="pone.0014771-Hadley1" ref-type="bibr">[45]</xref>, <xref rid="pone.0014771-Pagmantidis1" ref-type="bibr">[46]</xref> does not
compare directly with the marginal sub-optimal status observed in the volunteers on
the study. Furthermore, animal models have different tissue distribution and
expression of Se metabolising enzymes and, in particular, rats may not be ideal
models to study effects of all forms of Se, in particular monomethylated species
<xref rid="pone.0014771-Rooseboom1" ref-type="bibr">[47]</xref>.</p><p>In a longitudinal study of 39 human subjects, Sunde and colleagues found no
correlation between mRNA levels of SEPW1, selenoprotein P, selenoprotein H, GPX1,
GPX3, GPX4 and plasma Se over 24 weeks <xref rid="pone.0014771-Sunde1" ref-type="bibr">[48]</xref>. The explanation proposed was
that the volunteers were on the plateau of the response curve for these markers, and
as such had a replete Se status with respect to expression of the molecular markers
measured. However, the average plasma Se concentration was 1.13&#x000b1;0.16
&#x000b5;mol/l <xref rid="pone.0014771-Sunde1" ref-type="bibr">[48]</xref>
whereas the average plasma Se in volunteers recruited on the present study was
1.21&#x000b1;0.13 &#x000b5;mol/l <xref rid="pone.0014771-Hurst1" ref-type="bibr">[24]</xref>. It is likely therefore that our volunteers were on the
plateau of the response curve for SEPW1 and SEPR which would explain why
supplementation with additional Se, up to 200 &#x000b5;g/day, did not produce a
consistent significant change in gene expression of SEPW1 and SEPR. SEPW1 does,
however, present an exception at week 10 where mRNA levels were negatively
correlated with Se-yeast dose (up to 200 &#x000b5;g/day) when a steady state Se status
was achieved based on plasma Se data <xref rid="pone.0014771-Hurst1" ref-type="bibr">[24]</xref>. This change in SEPW1 gene expression would not have been
encountered by Sunde <italic>et al</italic>
<xref rid="pone.0014771-Sunde1" ref-type="bibr">[48]</xref> as their study
focussed on differences in molecular markers over a range of habitual intakes
estimated to be 27&#x02013;83 &#x000b5;g/day and the effect of Se supplementation on
SEPW1 gene expression was not investigated <xref rid="pone.0014771-Sunde1" ref-type="bibr">[48]</xref>.</p><p>Supplementation with Se-enriched onions demonstrated a consistent, albeit relatively
small, increase in the level of mRNA of all the selenoproteins tested, when compared
with the unenriched onion group, particularly SEPW1. SEPW1 significantly increased
in the Se-enriched onion group compared to the unenriched onion group. This result
was as expected from <italic>in vitro</italic> work with Se-methylselenocysteine
adapted human cells <xref rid="pone.0014771-Hurst2" ref-type="bibr">[49]</xref>, as the predominant form of Se in onions is
&#x003b3;-glutamyl methylselenocysteine (66&#x00025;) <xref rid="pone.0014771-Hurst1" ref-type="bibr">[24]</xref>, <xref rid="pone.0014771-Kotrebai1" ref-type="bibr">[50]</xref>. In contrast to the
Se-enriched onions which contain &#x0003c;9&#x00025; selenomethionine; the major form of
Se in Se-yeast is selenomethionine, constituting &#x0223c;60&#x00025; of the Se content
<xref rid="pone.0014771-Larsen1" ref-type="bibr">[51]</xref>.
Supplementation with 200 &#x000b5;g/day L-selenomethionine was shown to up-regulate
expression of 28 genes <xref rid="pone.0014771-Kibriya1" ref-type="bibr">[52]</xref> but the individuals selected had arsenic-induced
pre-malignant skin lesions and many of the genes found to be up-regulated were
involved in immunological and oxidative stress regulation, which would likely have
been differentially regulated in individuals suffering from this condition compared
to healthy individuals. Additionally, no selenoprotein genes were found to be
differentially regulated by the supplementation regimen. The effect of form of Se in
Se-enriched onions on expression of key genes encoding selenoproteins, plus
expression/activity of important selenoproteins warrants further investigation.</p><p>The lack of compelling evidence for the regulation of SEPR and to a lesser extent
SEPW1 expression in PMBC in response to Se supplementation, over the range of
intakes and time points tested, is likely to be partly due to high inter-individual
variation which would mask potentially relatively small changes in mRNA level. The
level of inter-individual variation in PBMC gene expression has been found to be
inherently high <xref rid="pone.0014771-Eady1" ref-type="bibr">[31]</xref>. In a previous intervention study using a dietary supplement
of 100 &#x000b5;g sodium selenite/day, the authors were only able to identify changes
of 1.2 fold difference between Se supplemented and un-supplemented individuals in
ribosomal protein L30 (RPL30), L37A (RPL37A) and eukaryotic translation elongation
factor 1 epsilon 1 (EEF1E1) genes <xref rid="pone.0014771-Pagmantidis2" ref-type="bibr">[53]</xref>. This was attributed to
the fact that the main control mechanisms of the targeted genes are predominantly at
the post-transcriptional level <xref rid="pone.0014771-Pagmantidis2" ref-type="bibr">[53]</xref>, which may also be the case for the genes we
investigated. Furthermore, although work with animal models has identified some
highly Se responsive mRNA species the majority of the selenoproteome appears to be
unaffected by dietary Se variation <xref rid="pone.0014771-Barnes2" ref-type="bibr">[54]</xref>, <xref rid="pone.0014771-Sunde2" ref-type="bibr">[55]</xref>. The effects of Se on gene expression may also be
form-specific and dose-specific, as highlighted by specific changes in SEPW1 and
SEPS1 in response to different treatments in the present study.</p><p>A significant increase was observed in SEPS1 mRNA at week 11, one week after
influenza vaccine was administered, but it should be noted that one limitation of
this study was the lack of a vaccine control group. SEPS1 is known to protect the
functional integrity of the endoplasmic reticulum by the removal of misfolded
proteins and to modulate cytokine production <xref rid="pone.0014771-Ye1" ref-type="bibr">[23]</xref>, <xref rid="pone.0014771-Curran1" ref-type="bibr">[56]</xref>. The modulation of cytokines is
hypothesised to function in a regulatory loop, whereby cytokines elicit increased
expression of SEPS1 which then inhibits the production of further cytokines <xref rid="pone.0014771-Gao1" ref-type="bibr">[57]</xref>. Our results are
the first observation of a Se dose-specific up-regulation in SEPS1 mRNA in response
to influenza vaccine, as a marker of immune function effects. The increase in SEPS1
expression in reaction to such a challenge concurs with its hypothesised key role in
the regulation of cytokines which control the body's inflammatory response
<xref rid="pone.0014771-Curran1" ref-type="bibr">[56]</xref>.</p><p>In conclusion, SEPW1 and SEPR were not sensitive molecular markers of exposure to
different forms and levels of Se, and did not significantly change after influenza
vaccine challenge in the population studied. However, quantification of mRNA levels
of SEPS1 in different Se-supplemented groups after influenza vaccine indicated a
dose-specific response in SEPS1 expression after vaccination. This potentially
important finding should be investigated further, especially in relation to the
potential role of SEPS1 in the immune response.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0014771.s001"><label>Figure S1</label><caption><p>Flow diagram to represent the number of volunteers who were screened and
recruited onto the study. Reproduced with permission by Hurst et al 2010
<xref rid="pone.0014771-Hurst1" ref-type="bibr">[24]</xref>.</p><p>(0.34 MB TIF)</p></caption><media xlink:href="pone.0014771.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0014771.s002"><label>Text S1</label><caption><p>Approval Letter from Norwich Ethics Committee</p><p>(0.08 MB DOC)</p></caption><media xlink:href="pone.0014771.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0014771.s003"><label>Protocol S1</label><caption><p>Trial Protocol</p><p>(0.23 MB DOC)</p></caption><media xlink:href="pone.0014771.s003.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0014771.s004"><label>Checklist S1</label><caption><p>CONSORT Checklist</p><p>(0.04 MB DOCX)</p></caption><media xlink:href="pone.0014771.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank the volunteers who participated in the study and the staff at the Human
Nutrition Unit, Institute of Food Research. We also thank Katrin Deiser,
Marie-Theres Drossel, Ben Thompson, Jana Lipfert and Anna Scheibschick for their
work on sample collection and GPx assays and Robert Foxall for completing the power
calculations at the design stage of the intervention trial.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The study was funded by the UK Food Standards Agency (grant NO5059), the
Institute of Food Research and the University of East Anglia. The Se-yeast
supplements and placebo tablets were donated by Pharma Nord, Denmark, and the
influenza vaccines were supplied by Masta Ltd, U.K. and Solvay, Netherlands. The
funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0014771-Rayman1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rayman</surname><given-names>MP</given-names></name></person-group>
<year>2008</year>
<article-title>Food-chain selenium and human health: emphasis on
intake.</article-title>
<source>Br J Nutr</source>
<volume>100</volume>
<fpage>254</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="pmid">18346308</pub-id></element-citation></ref><ref id="pone.0014771-Bleys1"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bleys</surname><given-names>J</given-names></name><name><surname>Navas-Acien</surname><given-names>A</given-names></name><name><surname>Guallar</surname><given-names>E</given-names></name></person-group>
<year>2008</year>
<article-title>Serum selenium levels and all-cause, cancer, and cardiovascular
mortality among US adults.</article-title>
<source>Arch Intern Med</source>
<volume>168</volume>
<fpage>404</fpage>
<lpage>410</lpage>
<pub-id pub-id-type="pmid">18299496</pub-id></element-citation></ref><ref id="pone.0014771-Combs1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Combs</surname><given-names>GF</given-names><suffix>Jr</suffix></name></person-group>
<year>2001</year>
<article-title>Impact of selenium and cancer-prevention findings on the
nutrition-health paradigm.</article-title>
<source>Nutr Cancer</source>
<volume>40</volume>
<fpage>6</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">11799925</pub-id></element-citation></ref><ref id="pone.0014771-Marmot1"><label>4</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Marmot</surname><given-names>M</given-names></name><name><surname>Atinmo</surname><given-names>T</given-names></name><name><surname>Byers</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hirohata</surname><given-names>T</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Food, Nutrition, Physical Activity, and the Prevention of Cancer:
a Global Perspective.</article-title>
<source>Research report. WCRF/AICR Expert Report</source>
<publisher-loc>Washington</publisher-loc>
<publisher-name>American Institute for Cancer Research</publisher-name>
<fpage>109</fpage>
<lpage>11</lpage>
</element-citation></ref><ref id="pone.0014771-Clark1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clark</surname><given-names>LC</given-names></name><name><surname>Combs</surname><given-names>GF</given-names><suffix>Jr</suffix></name><name><surname>Turnbull</surname><given-names>BW</given-names></name><name><surname>Slate</surname><given-names>EH</given-names></name><name><surname>Chalker</surname><given-names>DK</given-names></name><etal/></person-group>
<year>1996</year>
<article-title>Effects of selenium supplementation for cancer prevention in
patients with carcinoma of the skin. A randomized controlled trial.
Nutritional Prevention of Cancer Study Group.</article-title>
<source>JAMA</source>
<volume>276</volume>
<fpage>1957</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">8971064</pub-id></element-citation></ref><ref id="pone.0014771-Ip1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ip</surname><given-names>C</given-names></name><name><surname>Hayes</surname><given-names>C</given-names></name><name><surname>Budnick</surname><given-names>RM</given-names></name><name><surname>Ganther</surname><given-names>HE</given-names></name></person-group>
<year>1991</year>
<article-title>Chemical form of selenium, critical metabolites, and cancer
prevention.</article-title>
<source>Cancer Res</source>
<volume>51</volume>
<fpage>595</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="pmid">1824684</pub-id></element-citation></ref><ref id="pone.0014771-Hoffmann1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>PR</given-names></name><name><surname>Berry</surname><given-names>MJ</given-names></name></person-group>
<year>2008</year>
<article-title>The influence of selenium on immune responses.</article-title>
<source>Mol Nutr Food Res</source>
<volume>52</volume>
<fpage>1273</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">18384097</pub-id></element-citation></ref><ref id="pone.0014771-Broome1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Broome</surname><given-names>CS</given-names></name><name><surname>McArdle</surname><given-names>F</given-names></name><name><surname>Kyle</surname><given-names>JA</given-names></name><name><surname>Andrews</surname><given-names>F</given-names></name><name><surname>Lowe</surname><given-names>NM</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>An increase in selenium intake improves immune function and
poliovirus handling in adults with marginal selenium status.</article-title>
<source>Am J Clin Nutr</source>
<volume>80</volume>
<fpage>154</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">15213043</pub-id></element-citation></ref><ref id="pone.0014771-Rayman2"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rayman</surname><given-names>MP</given-names></name></person-group>
<year>1997</year>
<article-title>Dietary selenium: time to act.</article-title>
<source>BMJ</source>
<volume>314</volume>
<fpage>387</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">9040368</pub-id></element-citation></ref><ref id="pone.0014771-Thomson1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomson</surname><given-names>CD</given-names></name></person-group>
<year>2004</year>
<article-title>Assessment of requirements for selenium and adequacy of selenium
status: a review.</article-title>
<source>Eur J Clin Nutr</source>
<volume>58</volume>
<fpage>391</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="pmid">14985676</pub-id></element-citation></ref><ref id="pone.0014771-Burk1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burk</surname><given-names>RF</given-names></name><name><surname>Norsworthy</surname><given-names>BK</given-names></name><name><surname>Hill</surname><given-names>KE</given-names></name><name><surname>Motley</surname><given-names>AK</given-names></name><name><surname>Byrne</surname><given-names>DW</given-names></name></person-group>
<year>2006</year>
<article-title>Effects of chemical form of selenium on plasma biomarkers in a
high-dose human supplementation trial.</article-title>
<source>Cancer Epidemiol Biomarkers Prev</source>
<volume>15</volume>
<fpage>804</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">16614127</pub-id></element-citation></ref><ref id="pone.0014771-Neve1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Neve</surname><given-names>J</given-names></name></person-group>
<year>1995</year>
<article-title>Human selenium supplementation as assessed by changes in blood
selenium concentration and glutathione peroxidase activity.</article-title>
<source>J Trace Elem Med Biol</source>
<volume>9</volume>
<fpage>65</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="pmid">8825978</pub-id></element-citation></ref><ref id="pone.0014771-Burk2"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burk</surname><given-names>RF</given-names></name><name><surname>Hill</surname><given-names>KE</given-names></name><name><surname>Motley</surname><given-names>AK</given-names></name></person-group>
<year>2001</year>
<article-title>Plasma selenium in specific and non-specific
forms.</article-title>
<source>Biofactors</source>
<volume>14</volume>
<fpage>107</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">11568447</pub-id></element-citation></ref><ref id="pone.0014771-Patching1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patching</surname><given-names>SG</given-names></name><name><surname>Gardiner</surname><given-names>PH</given-names></name></person-group>
<year>1999</year>
<article-title>Recent developments in selenium metabolism and chemical
speciation: a review.</article-title>
<source>J Trace Elem Med Biol</source>
<volume>13</volume>
<fpage>193</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">10707342</pub-id></element-citation></ref><ref id="pone.0014771-Kryukov1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Castellano</surname><given-names>S</given-names></name><name><surname>Novoselov</surname><given-names>SV</given-names></name><name><surname>Lobanov</surname><given-names>AV</given-names></name><name><surname>Zehtab</surname><given-names>O</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Characterization of mammalian selenoproteomes.</article-title>
<source>Science</source>
<volume>300</volume>
<fpage>1439</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">12775843</pub-id></element-citation></ref><ref id="pone.0014771-Elsom1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elsom</surname><given-names>R</given-names></name><name><surname>Sanderson</surname><given-names>P</given-names></name><name><surname>Hesketh</surname><given-names>JE</given-names></name><name><surname>Jackson</surname><given-names>MJ</given-names></name><name><surname>Fairweather-Tait</surname><given-names>SJ</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Functional markers of selenium status: UK Food Standards Agency
workshop report.</article-title>
<source>Br J Nutr</source>
<volume>96</volume>
<fpage>980</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">17092391</pub-id></element-citation></ref><ref id="pone.0014771-Institute1"><label>17</label><element-citation publication-type="book">
<collab>Institute of Medicine. Dietary Reference Intakes for vitamin C, vitamin
E, selenium and carotenoids</collab>
<year>2000</year>
<publisher-loc>Washington DC</publisher-loc>
<publisher-name>National Academy Press</publisher-name>
</element-citation></ref><ref id="pone.0014771-Brown1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>KM</given-names></name><name><surname>Pickard</surname><given-names>K</given-names></name><name><surname>Nicol</surname><given-names>F</given-names></name><name><surname>Beckett</surname><given-names>GJ</given-names></name><name><surname>Duthie</surname><given-names>GG</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>Effects of organic and inorganic selenium supplementation on
selenoenzyme activity in blood lymphocytes, granulocytes, platelets and
erythrocytes.</article-title>
<source>Clin Sci (Lond)</source>
<volume>98</volume>
<fpage>593</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">10781391</pub-id></element-citation></ref><ref id="pone.0014771-Ashton1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashton</surname><given-names>K</given-names></name><name><surname>Hooper</surname><given-names>L</given-names></name><name><surname>Harvey</surname><given-names>LJ</given-names></name><name><surname>Hurst</surname><given-names>R</given-names></name><name><surname>Casgrain</surname><given-names>A</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Methods of assessment of selenium status in humans: a systematic
review.</article-title>
<source>Am J Clin Nutr</source>
<volume>89</volume>
<fpage>2025S</fpage>
<lpage>2039S</lpage>
<pub-id pub-id-type="pmid">19420095</pub-id></element-citation></ref><ref id="pone.0014771-Xia1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Hill</surname><given-names>KE</given-names></name><name><surname>Byrne</surname><given-names>DW</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Burk</surname><given-names>RF</given-names></name></person-group>
<year>2005</year>
<article-title>Effectiveness of selenium supplements in a low-selenium area of
China.</article-title>
<source>Am J Clin Nutr</source>
<volume>81</volume>
<fpage>829</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">15817859</pub-id></element-citation></ref><ref id="pone.0014771-Jeong1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jeong</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>TS</given-names></name><name><surname>Chung</surname><given-names>YW</given-names></name><name><surname>Lee</surname><given-names>BJ</given-names></name><name><surname>Kim</surname><given-names>IY</given-names></name></person-group>
<year>2002</year>
<article-title>Selenoprotein W is a glutathione-dependent antioxidant in
vivo.</article-title>
<source>FEBS Lett</source>
<volume>517</volume>
<fpage>225</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">12062442</pub-id></element-citation></ref><ref id="pone.0014771-Kryukov2"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Kumar</surname><given-names>RA</given-names></name><name><surname>Koc</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Gladyshev</surname><given-names>VN</given-names></name></person-group>
<year>2002</year>
<article-title>Selenoprotein R is a zinc-containing stereo-specific methionine
sulfoxide reductase.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>99</volume>
<fpage>4245</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="pmid">11929995</pub-id></element-citation></ref><ref id="pone.0014771-Ye1"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Shibata</surname><given-names>Y</given-names></name><name><surname>Yun</surname><given-names>C</given-names></name><name><surname>Ron</surname><given-names>D</given-names></name><name><surname>Rapoport</surname><given-names>TA</given-names></name></person-group>
<year>2004</year>
<article-title>A membrane protein complex mediates retro-translocation from the
ER lumen into the cytosol.</article-title>
<source>Nature</source>
<volume>429</volume>
<fpage>841</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">15215856</pub-id></element-citation></ref><ref id="pone.0014771-Hurst1"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hurst</surname><given-names>R</given-names></name><name><surname>Armah</surname><given-names>CN</given-names></name><name><surname>Hart</surname><given-names>DJ</given-names></name><name><surname>Teucher</surname><given-names>B</given-names></name><name><surname>Dainty</surname><given-names>JR</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Establishing optimal selenium status: results of a randomised,
double-blind, placebo-controlled trial.</article-title>
<source>Am J Clin Nut</source>
<volume>91</volume>
<fpage>923</fpage>
<lpage>931</lpage>
</element-citation></ref><ref id="pone.0014771-Bradford1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bradford</surname><given-names>MM</given-names></name></person-group>
<article-title>A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding
(1976).</article-title>
<source>Anal Biochem</source>
<volume>72</volume>
<fpage>248</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="pmid">942051</pub-id></element-citation></ref><ref id="pone.0014771-Drabkin1"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Drabkin</surname><given-names>DL</given-names></name></person-group>
<year>1949</year>
<article-title>The standardization of hemoglobin measurement.</article-title>
<source>Am J Med Sci</source>
<volume>217</volume>
<fpage>710</fpage>
</element-citation></ref><ref id="pone.0014771-Paglia1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paglia</surname><given-names>DE</given-names></name><name><surname>Valentine</surname><given-names>WN</given-names></name></person-group>
<year>1967</year>
<article-title>Studies on the quantitative and qualitative characterization of
erythrocyte glutathione peroxidase.</article-title>
<source>J Lab Clin Med</source>
<volume>70</volume>
<fpage>158</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="pmid">6066618</pub-id></element-citation></ref><ref id="pone.0014771-Smith1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>AD</given-names></name><name><surname>Levander</surname><given-names>OA</given-names></name></person-group>
<year>2002</year>
<article-title>High-throughput 96-well microplate assays for determining
specific activities of glutathione peroxidase and thioredoxin
reductase.</article-title>
<source>Methods Enzymol</source>
<volume>347</volume>
<fpage>113</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">11898400</pub-id></element-citation></ref><ref id="pone.0014771-Thomson2"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomson</surname><given-names>CD</given-names></name></person-group>
<year>1985</year>
<article-title>Selenium-dependent and non-selenium-dependent glutathione
peroxidase in human tissues of New Zealand residents.</article-title>
<source>Biochem Int</source>
<volume>10</volume>
<fpage>673</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">4026872</pub-id></element-citation></ref><ref id="pone.0014771-Bao1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Chambers</surname><given-names>SJ</given-names></name><name><surname>Williamson</surname><given-names>G</given-names></name></person-group>
<year>1995</year>
<article-title>Direct separation of hydroperoxy- and hydroxy-phosphatidylcholine
derivatives: application to the assay of phospholipid hydroperoxide
glutathione peroxidase.</article-title>
<source>Anal Biochem</source>
<volume>224</volume>
<fpage>395</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">7710098</pub-id></element-citation></ref><ref id="pone.0014771-Eady1"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eady</surname><given-names>JJ</given-names></name><name><surname>Wortley</surname><given-names>GM</given-names></name><name><surname>Wormstone</surname><given-names>YM</given-names></name><name><surname>Hughes</surname><given-names>JC</given-names></name><name><surname>Astley</surname><given-names>SB</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Variation in gene expression profiles of peripheral blood
mononuclear cells from healthy volunteers.</article-title>
<source>Physiol Genomics</source>
<volume>22</volume>
<fpage>402</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">16014386</pub-id></element-citation></ref><ref id="pone.0014771-Applied1"><label>32</label><mixed-citation publication-type="other">
<comment>Applied Biosystems Prism 7700 SDS User Bulletin #2. Available:
<ext-link ext-link-type="uri" xlink:href="http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_040980.pdf">http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_040980.pdf</ext-link>,
via the internet. Accessed 12 June 2004</comment>
</mixed-citation></ref><ref id="pone.0014771-Vandesompele1"><label>33</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Vandesompele</surname><given-names>J</given-names></name><name><surname>De Preter</surname><given-names>K</given-names></name><name><surname>Pattyn</surname><given-names>F</given-names></name><name><surname>Poppe</surname><given-names>B</given-names></name><name><surname>Van Roy</surname><given-names>N</given-names></name><etal/></person-group>
<year>2002</year>
<comment>Accurate normalization of real-time quantitative RT-PCR data by
geometric averaging of multiple internal control genes. Genome Biol 3
Available: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC126239/">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC126239/</ext-link> via the
Internet. Accessed 15 Aug 2005</comment>
</element-citation></ref><ref id="pone.0014771-Loseke1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loseke</surname><given-names>S</given-names></name><name><surname>Grage-Griebenow</surname><given-names>E</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Gehlhar</surname><given-names>K</given-names></name><name><surname>Bufe</surname><given-names>A</given-names></name></person-group>
<year>2003</year>
<article-title>Differential expression of IFN-alpha subtypes in human PBMC:
evaluation of novel real-time PCR assays.</article-title>
<source>J Immunol Methods</source>
<volume>276</volume>
<fpage>207</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="pmid">12738374</pub-id></element-citation></ref><ref id="pone.0014771-R1"><label>35</label><element-citation publication-type="journal">
<collab>R Development Core Team</collab>
<comment>R: a language and environment for statistical computing. R Foundation
of Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org">http://www.R-project.org</ext-link>. Accessed 23 June 2008</comment>
</element-citation></ref><ref id="pone.0014771-Thomson3"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomson</surname><given-names>CD</given-names></name><name><surname>Robinson</surname><given-names>MF</given-names></name><name><surname>Butler</surname><given-names>JA</given-names></name><name><surname>Whanger</surname><given-names>PD</given-names></name></person-group>
<year>1993</year>
<article-title>Long-term supplementation with selenate and selenomethionine:
selenium and glutathione peroxidase (EC 1.11.1.9) in blood components of New
Zealand women.</article-title>
<source>Br J Nutr</source>
<volume>69</volume>
<fpage>577</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="pmid">8490010</pub-id></element-citation></ref><ref id="pone.0014771-Hawkes1"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hawkes</surname><given-names>WC</given-names></name><name><surname>Richter</surname><given-names>BD</given-names></name><name><surname>Alkan</surname><given-names>Z</given-names></name><name><surname>Souza</surname><given-names>EC</given-names></name><name><surname>Derricote</surname><given-names>M</given-names></name></person-group>
<year>2008</year>
<article-title>Response of selenium status indicators to supplementation of
healthy North American men with high-selenium yeast.</article-title>
<source>Biol Trace Elem Res</source>
<volume>122</volume>
<fpage>107</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">18193397</pub-id></element-citation></ref><ref id="pone.0014771-Neve2"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Neve</surname><given-names>J</given-names></name><name><surname>Vertongen</surname><given-names>F</given-names></name><name><surname>Capel</surname><given-names>P</given-names></name></person-group>
<year>1988</year>
<article-title>Selenium supplementation in healthy Belgian adults: response in
platelet glutathione peroxidase activity and other blood
indices.</article-title>
<source>Am J Clin Nutr</source>
<volume>48</volume>
<fpage>139</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">3389320</pub-id></element-citation></ref><ref id="pone.0014771-Deagen1"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deagen</surname><given-names>JT</given-names></name><name><surname>Butler</surname><given-names>JA</given-names></name><name><surname>Zachara</surname><given-names>BA</given-names></name><name><surname>Whanger</surname><given-names>PD</given-names></name></person-group>
<year>1993</year>
<article-title>Determination of the distribution of selenium between glutathione
peroxidase, selenoprotein P, and albumin in plasma.</article-title>
<source>Anal Biochem</source>
<volume>208</volume>
<fpage>176</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">8434786</pub-id></element-citation></ref><ref id="pone.0014771-Akesson1"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akesson</surname><given-names>B</given-names></name><name><surname>Bellew</surname><given-names>T</given-names></name><name><surname>Burk</surname><given-names>RF</given-names></name></person-group>
<year>1994</year>
<article-title>Purification of selenoprotein P from human
plasma.</article-title>
<source>Biochim Biophys Acta</source>
<volume>1204</volume>
<fpage>243</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">8142465</pub-id></element-citation></ref><ref id="pone.0014771-Arab1"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arab</surname><given-names>L</given-names></name></person-group>
<year>2004</year>
<article-title>Individualized nutritional recommendations: do we have the
measurements needed to assess risk and make dietary
recommendations?</article-title>
<source>Proc Nutr Soc</source>
<volume>63</volume>
<fpage>167</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">15070447</pub-id></element-citation></ref><ref id="pone.0014771-Kussmann1"><label>42</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kussmann</surname><given-names>M</given-names></name><name><surname>Raymond</surname><given-names>F</given-names></name><name><surname>Affolter</surname><given-names>M</given-names></name></person-group>
<year>2006</year>
<article-title>OMICS-driven biomarker discovery in nutrition and
health.</article-title>
<source>J Biotechnol</source>
<volume>124</volume>
<fpage>758</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="pmid">16600411</pub-id></element-citation></ref><ref id="pone.0014771-Kipp1"><label>43</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kipp</surname><given-names>A</given-names></name><name><surname>Banning</surname><given-names>A</given-names></name><name><surname>van Schothorst</surname><given-names>EM</given-names></name><name><surname>M&#x000e9;plan</surname><given-names>C</given-names></name><name><surname>Schomburg</surname><given-names>L</given-names></name><name><surname>Evelo</surname><given-names>C</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Four selenoproteins, protein biosynthesis, and Wnt signalling are
particularly sensitive to limited selenium intake in mouse
colon.</article-title>
<source>Mol Nutr Food Res</source>
<volume>53</volume>
<fpage>1561</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">19810021</pub-id></element-citation></ref><ref id="pone.0014771-Barnes1"><label>44</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barnes</surname><given-names>KM</given-names></name><name><surname>Evenson</surname><given-names>JK</given-names></name><name><surname>Raines</surname><given-names>AM</given-names></name><name><surname>Sunde</surname><given-names>RA</given-names></name></person-group>
<year>2009</year>
<article-title>Transcript analysis of the selenoproteome indicates that dietary
selenium requirements of rats based on selenium-regulated selenoprotein mRNA
levels are uniformly less than those based on glutathione peroxidase
activity.</article-title>
<source>J Nutr</source>
<volume>139</volume>
<issue>2</issue>
<fpage>199</fpage>
<lpage>206</lpage>
<comment>Available: <ext-link ext-link-type="uri" xlink:href="http://jn.nutrition.org/cgi/content/full/139/2/199">http://jn.nutrition.org/cgi/content/full/139/2/199</ext-link> via the
internet. Accessed 12 Oct 2009</comment>
<pub-id pub-id-type="pmid">19106321</pub-id></element-citation></ref><ref id="pone.0014771-Hadley1"><label>45</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hadley</surname><given-names>KB</given-names></name><name><surname>Sunde</surname><given-names>RA</given-names></name></person-group>
<year>2001</year>
<article-title>Selenium regulation of thioredoxin reductase activity and mRNA
levels in rat liver.</article-title>
<source>J Nutr Biochemistry</source>
<volume>12</volume>
<fpage>693</fpage>
<lpage>702</lpage>
</element-citation></ref><ref id="pone.0014771-Pagmantidis1"><label>46</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pagmantidis</surname><given-names>V</given-names></name><name><surname>Bermano</surname><given-names>G</given-names></name><name><surname>Villette</surname><given-names>S</given-names></name><name><surname>Broom</surname><given-names>I</given-names></name><name><surname>Arthur</surname><given-names>J</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Effects of Se-depletion on glutathione peroxidase and
selenoprotein W gene expression in the colon.</article-title>
<source>FEBS Lett</source>
<volume>579</volume>
<fpage>792</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">15670848</pub-id></element-citation></ref><ref id="pone.0014771-Rooseboom1"><label>47</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rooseboom</surname><given-names>M</given-names></name><name><surname>Vermeulen</surname><given-names>NP</given-names></name><name><surname>Groot</surname><given-names>EJ</given-names></name><name><surname>Commandeur</surname><given-names>JN</given-names></name></person-group>
<year>2002</year>
<article-title>Tissue distribution of cytosolic beta-elimination reactions of
selenocysteine Se-conjugates in rat and human.</article-title>
<source>Chem Biol Interact</source>
<volume>140</volume>
<fpage>243</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">12204580</pub-id></element-citation></ref><ref id="pone.0014771-Sunde1"><label>48</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sunde</surname><given-names>RA</given-names></name><name><surname>Paterson</surname><given-names>E</given-names></name><name><surname>Evenson</surname><given-names>JK</given-names></name><name><surname>Barnes</surname><given-names>KM</given-names></name><name><surname>Lovegrove</surname><given-names>JA</given-names></name></person-group>
<year>2008</year>
<article-title>Longitudinal selenium status in healthy British adults:
assessment using biochemical and molecular biomarkers.</article-title>
<source>Br J Nutr</source>
<volume>99</volume>
<issue>Suppl 3</issue>
<fpage>S37</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">18598587</pub-id></element-citation></ref><ref id="pone.0014771-Hurst2"><label>49</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hurst</surname><given-names>R</given-names></name><name><surname>Elliott</surname><given-names>RM</given-names></name><name><surname>Goldson</surname><given-names>AJ</given-names></name><name><surname>Fairweather-Tait</surname><given-names>SJ</given-names></name></person-group>
<year>2008</year>
<article-title>Se-methylselenocysteine alters collagen gene and protein
expression in human prostate cells.</article-title>
<source>Cancer Lett</source>
<volume>269</volume>
<fpage>117</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="pmid">18514395</pub-id></element-citation></ref><ref id="pone.0014771-Kotrebai1"><label>50</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kotrebai</surname><given-names>M</given-names></name><name><surname>Birringer</surname><given-names>M</given-names></name><name><surname>Tyson</surname><given-names>JF</given-names></name><name><surname>Block</surname><given-names>E</given-names></name><name><surname>Uden</surname><given-names>PC</given-names></name></person-group>
<year>2000</year>
<article-title>Selenium speciation in enriched and natural samples by
HPLC-ICP-MS and HPLC-ESI-MS with perfluorinated carboxylic acid ion-pairing
agents.</article-title>
<source>Analyst</source>
<volume>125</volume>
<fpage>71</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">10885064</pub-id></element-citation></ref><ref id="pone.0014771-Larsen1"><label>51</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Larsen</surname><given-names>EH</given-names></name><name><surname>Hansen</surname><given-names>M</given-names></name><name><surname>Paulin</surname><given-names>H</given-names></name><name><surname>Moesgaard</surname><given-names>S</given-names></name><name><surname>Reid</surname><given-names>M</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Speciation and bioavailability of selenium in yeast-based
intervention agents used in cancer chemoprevention studies.</article-title>
<source>J AOAC Int</source>
<volume>87</volume>
<fpage>225</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">15084104</pub-id></element-citation></ref><ref id="pone.0014771-Kibriya1"><label>52</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kibriya</surname><given-names>MG</given-names></name><name><surname>Jasmine</surname><given-names>F</given-names></name><name><surname>Argos</surname><given-names>M</given-names></name><name><surname>Verret</surname><given-names>WJ</given-names></name><name><surname>Rakibuz-Zaman</surname><given-names>M</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Changes in gene expression profiles in response to selenium
supplementation among individuals with arsenic-induced pre-malignant skin
lesions.</article-title>
<source>Toxicol Lett</source>
<volume>169</volume>
<fpage>162</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">17293063</pub-id></element-citation></ref><ref id="pone.0014771-Pagmantidis2"><label>53</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pagmantidis</surname><given-names>V</given-names></name><name><surname>Meplan</surname><given-names>C</given-names></name><name><surname>van Schothorst</surname><given-names>EM</given-names></name><name><surname>Keijer</surname><given-names>J</given-names></name><name><surname>Hesketh</surname><given-names>JE</given-names></name></person-group>
<year>2008</year>
<article-title>Supplementation of healthy volunteers with nutritionally relevant
amounts of selenium increases the expression of lymphocyte protein
biosynthesis genes.</article-title>
<source>Am J Clin Nutr</source>
<volume>87</volume>
<fpage>181</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">18175754</pub-id></element-citation></ref><ref id="pone.0014771-Barnes2"><label>54</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barnes</surname><given-names>KM</given-names></name><name><surname>Evenson</surname><given-names>JK</given-names></name><name><surname>Raines</surname><given-names>AM</given-names></name><name><surname>Sunde</surname><given-names>RA</given-names></name></person-group>
<year>2009</year>
<article-title>Transcript analysis of the selenoproteome indicates that dietary
selenium requirements of rats based on selenium-regulated selenoprotein mRNA
levels are uniformly less than those based on glutathione peroxidase
activity.</article-title>
<source>J Nutr</source>
<volume>139</volume>
<fpage>199</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="pmid">19106321</pub-id></element-citation></ref><ref id="pone.0014771-Sunde2"><label>55</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sunde</surname><given-names>RA</given-names></name><name><surname>Raines</surname><given-names>AM</given-names></name><name><surname>Barnes</surname><given-names>KM</given-names></name><name><surname>Evenson</surname><given-names>JK</given-names></name></person-group>
<year>2009</year>
<article-title>Selenium status highly regulates selenoprotein mRNA levels for
only a subset of the selenoproteins in the selenoproteome.</article-title>
<source>Biosci Rep</source>
<volume>29</volume>
<fpage>329</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="pmid">19076066</pub-id></element-citation></ref><ref id="pone.0014771-Curran1"><label>56</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curran</surname><given-names>JE</given-names></name><name><surname>Jowett</surname><given-names>JB</given-names></name><name><surname>Elliott</surname><given-names>KS</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Gluschenko</surname><given-names>K</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Genetic variation in selenoprotein S influences inflammatory
response.</article-title>
<source>Nat Genet</source>
<volume>37</volume>
<fpage>1234</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">16227999</pub-id></element-citation></ref><ref id="pone.0014771-Gao1"><label>57</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Hannan</surname><given-names>NR</given-names></name><name><surname>Wanyonyi</surname><given-names>S</given-names></name><name><surname>Konstantopolous</surname><given-names>N</given-names></name><name><surname>Pagnon</surname><given-names>J</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Activation of the selenoprotein SEPS1 gene expression by
pro-inflammatory cytokines in HepG2 cells.</article-title>
<source>Cytokine</source>
<volume>33</volume>
<fpage>246</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">16574427</pub-id></element-citation></ref></ref-list></back></article>